The novel candidate, ASAP1, has also been reported to be frequently amplified, accompanied by enhanced expression, in different types of cancers, including pancreatic ductal adenocarcinoma, prostate cancer, and melanoma [34, 42], exceptionally in primary BC where overexpression of ASAP1 was described to be independent of ASAP1 amplification [43]. Here, ASAP1 is linked to cancer.